COPD patient News
-
RESTECH and VIVISOL together to bring innovative monitoring at home of COPD patients
RESTECH srl and VIVISOL has established a long-term commercial partnership to commercialize the RESMON PRO DIARY and its innovative algorithm for the detection of the risk of exacerbation in COPD patients. Thanks to this collaboration RESTECH will be able to consolidate its operative know-how and bring the latest innovations in home monitoring directly in the homes of COPD patients of the main ...
By Restech Srl
-
CHROMED trial completed successfully
Restech, in its role of technical manager and together with all the partner of the project, successfully concluded the CHROMED trial. With 312 patients enrolled and studied for 9 months by 6 clinical centers in 5 EU Countries, CHROMED has been the largest international multi-center randomized control trial evaluating the effectiveness of an integrated telecare approach for COPD patients based on ...
By Restech Srl
-
Restech announces the clinical validation of the Resmon Pro Diary to remotely monitor COPD at home.
The CHROMED trial, one of the largest clinical trial using FOT to monitor remotely COPD patients and prevent exacerbation has now been published on the American Journal of Respiratory and Critical care medicine! Using the RESMON PRO DIARY (the home version of the well proven, hospital, clinical unit, the RESMON PRO FULL), 312 patients from 5 different European countries have been successfully ...
By Restech Srl
-
Smart phone helper for COPD patients
A smart phone and a connection to the “internet of things” could allow people with chronic lung disease to avoid risky areas where environmental conditions, pollution and weather might exacerbate their symptoms. Details of a framework that would hook into networks of sensors and provide patients with timely alerts are reported this month in the International Journal of Computational ...
-
Circassia Announces FDA Approval of Duaklir for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Duaklir® is a fixed-dose combination ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with ...
-
Showcase
AioCare system could be successfully applied in primary healthcare Centers.
The role of spirometry in diagnosing and monitoring chronic obstructive airway diseases is crucial. According to WHO, the demonstration of irreversible airway obstruction is essential for diagnosing chronic obstructive pulmonary disease (COPD), which is the third leading cause of death worldwide. It is estimated that up to 67–81% of patients with COPD remain undiagnosed. Mobile phone-linked ...
By AioCare
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Oxford, UK – 29 March 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Tudorza®’s supplemental New Drug Application (sNDA) for the inclusion of unique new clinical data in the product’s ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added to label – – Tudorza® is the only product in its class with these data in the label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US ...
-
Spire Health Presents Interim Results on Anticipating Patient Hospitalizations using Industry’s Leading Remote Respiration Monitor
SAN FRANCISCO,CA – May 14, 2021 -- Spire Health, the leading provider of respiratory remote patient monitoring (RPM), today announced interim results from a clinical trial demonstrating the predictive capabilities and long-term patient adherence of theSpire RPM system. The results will be presented in two ePosters at the 2021 ATS International Conference, held virtually from May 14-19th. ...
By Spire Health
-
Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza Phase IV and Duaklir Phase III Studies
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® Pressair® phase IV ASCENT study and Duaklir® Pressair® phase III AMPLIFY study at the American Thoracic Society (ATS) 2018 International ...
-
Circassia Announces Duaklir New Drug Application (NDA) and Tudorza Supplemental NDA Accepted for Review by FDA
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that the United States Food and Drug Administration (FDA) has confirmed it has completed its validation for completeness, and accepted for filing and review, the previously submitted Duaklir® New Drug Application ...
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
-
CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the ...
-
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
Beyond Air, Inc. (NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
-
Circassia Announces Submission of Duaklir New Drug Application and Tudorza Supplemental New Drug Application in the United States
Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the submission of a New Drug ...
-
Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast of the presentation will be available ...
-
Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Bank of America Securities 2022 Healthcare Conference in Las Vegas. Management is scheduled to present on Tuesday, May 10, 2022, at 12:40 PM PT / 3:40 PM ET. A live and archived webcast of the presentation ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you